TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $121.6 million versus the consensus estimate of $109.5 million.

GUIDANCE:

TransMedics Group sees FY 2025 revenue of $530-552 million, versus the consensus of $521.6 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.